Price · as of 2025
$17.44
Market cap 5.89B
Valuation
| Metric | Value | Upside |
|---|---|---|
| IC Value | $6.07 | -65% |
| P/E | 51.45 | |
| P/B | -52.37 | |
| P/S | 1.23 | |
| EV/EBITDA | 10.16 | |
| PEG | — | |
| P/TBV | -3.01 |
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | IC | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $11.91 | $23.96 | |||
| 2019 | $3.46 | $13.37 | |||
| 2020 | $6.02 | $63.98 | |||
| 2021 | $4.12 | $30.99 | |||
| 2022 | $1.53 | $20.37 | |||
| 2023 | $5.39 | $17.30 | |||
| 2024 | $8.90 | $14.71 | |||
| 2025 | $11.83 | $27.34 |
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Line items
Line items
Line items
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
- CEO
- Chirag K. Patel
- Employees
- 8.5K
- Beta
- 1.26
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | IC Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | Value | Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AMRX | Amneal Pharmaceuticals, I… | $17.44 | 5.89B | $27.34 | +57% | 51.45 | -52.37 | 1.23 | 10.16 | — | -3.01 | 37.63% | 14.02% | 2.39% | -80.04% | 16.45% | 2.01% | -38.65 | 1.75 | 2.17 | 1.42 | 4.02 | -157.89% | 8.05% | 22.63% | 7.28% | 0.39 | 11.42% | 0.00% | 0.00% | 1.54% | 14.50 | 22.72 | 2.03 | 1.94 |
| BHC | Bausch Health Companies I… | $6.29 | 2.35B | $59.82 | +851% | 15.33 | -3.33 | 0.18 | 6.83 | — | -0.11 | 70.65% | 21.28% | 1.53% | -13.10% | 4.52% | 0.45% | -38.35 | 1.36 | 1.47 | 0.88 | 6.26 | -430.77% | 6.66% | -20.40% | 54.52% | 0.34 | 5.18% | 0.00% | 0.00% | 41.33% | 9.94 | 21.66 | 2.12 | 0.28 |
| DYN | Dyne Therapeutics, Inc. | $26.17 | 4.89B | — | — | -5.16 | 2.37 | — | -2.77 | -173.83 | 2.37 | 0.00% | 0.00% | 0.00% | -55.71% | 878.42% | -47.52% | 0.02 | -75.61 | 22.25 | 21.94 | 1.99 | 2.97% | — | 37.45% | -17.60% | -7.96 | 760.11% | 0.00% | 0.00% | 20.06% | -2.59 | -2.99 | — | 4.57 |
| INDV | Indivior Pharmaceuticals … | $38.73 | 4.83B | $35.09 | -9% | 18.52 | -39.68 | 3.14 | 13.31 | 0.17 | -38.89 | 80.15% | 21.39% | 16.95% | -94.17% | -198.17% | 16.65% | -3.58 | 5.89 | 0.71 | 0.49 | 0.51 | 10833.33% | 4.29% | -1980.00% | -2.42% | -0.03 | 80.00% | 0.00% | 0.00% | 0.28% | 15.26 | -43.03 | 3.26 | 3.00 |
| LNTH | Lantheus Holdings, Inc. | $101.50 | 6.61B | $126.56 | +25% | 22.97 | 4.92 | 3.48 | 13.94 | — | 42.08 | 61.10% | 20.16% | 15.15% | 21.45% | 21.57% | 11.10% | 0.57 | 15.74 | 2.70 | 2.15 | 0.64 | -21.79% | 0.50% | -28.20% | 6.60% | 1.17 | 33.02% | 0.00% | 0.00% | 5.59% | 18.10 | 15.89 | 3.65 | 4.71 |
| MIRM | Mirum Pharmaceuticals, In… | $105.79 | 6.45B | $44.25 | -58% | -194.79 | 14.46 | 8.73 | 260.79 | — | 84.64 | 80.71% | -4.25% | -4.48% | -8.65% | -8.61% | -3.09% | 1.02 | -1.54 | 2.67 | 2.46 | 1.32 | -74.59% | 54.74% | 488.01% | 1.21% | 0.27 | 21.36% | 0.00% | 0.00% | 1.59% | -202.71 | 81.77 | 8.61 | 5.08 |
| NVST | Envista Holdings Corp | $28.66 | 4.66B | $33.17 | +16% | 87.97 | 1.33 | 1.52 | 13.71 | — | 34.20 | 55.02% | 8.30% | 1.73% | 1.56% | 2.61% | 0.85% | 0.51 | 6.17 | 2.38 | 1.93 | 1.17 | -104.31% | 8.32% | -23.89% | 5.57% | 0.32 | 6.67% | 0.00% | 0.00% | 6.27% | 20.03 | 19.62 | 1.66 | 1.71 |
| PRGO | Perrigo Company plc | $13.27 | 1.84B | $9.23 | -30% | -0.90 | 0.43 | 0.30 | -5.88 | -0.12 | -0.85 | 35.14% | 8.07% | -33.51% | -38.66% | 4.99% | -15.42% | 1.35 | 2.11 | 2.76 | 1.13 | -4.31 | 723.20% | -2.75% | -40.68% | 11.56% | 0.24 | 2.11% | 12.69% | -11.40% | 12.69% | 13.67 | 32.34 | 1.10 | 0.41 |
| SUPN | Supernus Pharmaceuticals,… | $46.91 | 2.72B | $50.52 | +8% | -73.09 | 2.65 | 3.92 | 59.95 | — | 7.67 | 89.63% | -5.13% | -5.36% | -3.68% | -4.11% | -2.73% | 0.04 | — | 1.90 | 1.47 | -2.06 | -151.52% | 8.63% | -73.14% | 1.63% | 0.14 | 6.52% | 0.00% | 0.00% | 1.86% | -69.17 | 55.44 | 3.55 | 5.49 |
| TLX | Telix Pharmaceuticals Lim… | $10.42 | 3.53B | $16.25 | +56% | -351.07 | 6.03 | 3.11 | 53.09 | — | -14.11 | 53.11% | 2.21% | -0.89% | -1.80% | 3.44% | -0.65% | 1.12 | 0.48 | 1.43 | 1.21 | 6.10 | -122.57% | 53.91% | -388.42% | -2.21% | -0.07 | -10.69% | 0.00% | 0.00% | 0.00% | 159.09 | -51.19 | 3.52 | 2.61 |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.07 ÷ $17.44) − 1 = -65.19% (IC, example).